Checkpoint inhibitors are the standard treatment for multiple common cancers by blocking the activation of programmed cell death proteins (PD-1). Current diagnostics for predicting response to immunotherapy, using programmed cell death ligand (PD-L1) immunohistochemistry, have poor accuracy in predicting tumor response.
Revive Research Institute is collaborating with Cofactor Genomics Inc. to validate a new approach that delivers improved predictions with greater accuracy. The goal of this biospecimen collection research is to prove the new approach will be predictive of the efficacy of immunotherapy in patients with specific cancer indications who are undergoing treatment with a PD-L1 inhibitor.
- Adults 18 years of age or older, male or female
- Must have a disease of interest (currently head and neck squamous cell carcinoma, HNSCC)
- Must have received or be scheduled to receive at least one dose of anti-PD-1/PD-L1 immunotherapy
- Additional criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the biospecimen collection study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.